Received Nov 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 5H777 | — |
patient was administered with two doses of the AREXVY vaccine; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 74-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 5H777, expiry date 25-OCT-2025) for prophylaxis. Previously administered products included Arexvy (received 1st dose on 10-OCT-2024 with batch number 3Y7P4 and lot expiry 21-MAR-2025). On 03-OCT-2025, the patient received the 2nd dose of Arexvy. On 03-OCT-2025, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: patient was administered with two doses of the AREXVY vaccine). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 07-NOV-2025 The reporter reported that the patient was administered with two doses of the Arexvy vaccine (two dose) almost one year apart and needs further guidance/advise. Vaccination date, vaccine detail and patient demographics (all for two doses) were obtained in this call. No further information was obtained in this call. The vaccine administration facility was the same as primary reporter.